New cocktail of drugs shows promise for tough colorectal cancer
NCT ID NCT04362839
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial tested a combination of regorafenib (a targeted therapy) plus two immunotherapy drugs (nivolumab and ipilimumab) in 39 patients with advanced colorectal cancer that had spread and stopped responding to chemotherapy. The goal was to find the safest dose and check for side effects. The approach aims to both block cancer growth and boost the immune system to attack tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- regorafenib, nivolumab, and ipilimumab
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with hard-to-treat colorectal cancer that hasn't responded to chemotherapy.
- What could go wrong
- This is an early phase 1 trial with only 39 participants, focused on safety and dosing. The combination may cause significant side effects, and it's too early to know if it will improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLON ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new blood test spot colorectal cancer return earlier?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can two immune boosters outsmart Chemo-Resistant colon cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a four-drug cocktail shrink hard-to-treat colorectal cancer?